Logo image of MLSS

MILESTONE SCIENTIFIC INC (MLSS) Stock Fundamental Analysis

NYSEARCA:MLSS - NYSE Arca - US59935P2092 - Common Stock - Currency: USD

1.02  +0.13 (+13.97%)

After market: 1.02 0 (0%)

Fundamental Rating

2

Taking everything into account, MLSS scores 2 out of 10 in our fundamental rating. MLSS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of MLSS have multiple concerns. While showing a medium growth rate, MLSS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

MLSS had negative earnings in the past year.
MLSS had a negative operating cash flow in the past year.
In the past 5 years MLSS always reported negative net income.
MLSS had a negative operating cash flow in each of the past 5 years.
MLSS Yearly Net Income VS EBIT VS OCF VS FCFMLSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

With a Return On Assets value of -48.11%, MLSS is not doing good in the industry: 65.61% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -80.81%, MLSS is in line with its industry, outperforming 40.74% of the companies in the same industry.
Industry RankSector Rank
ROA -48.11%
ROE -80.81%
ROIC N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
MLSS Yearly ROA, ROE, ROICMLSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

MLSS has a Gross Margin of 74.56%. This is amongst the best in the industry. MLSS outperforms 87.30% of its industry peers.
In the last couple of years the Gross Margin of MLSS has grown nicely.
The Profit Margin and Operating Margin are not available for MLSS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
MLSS Yearly Profit, Operating, Gross MarginsMLSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

MLSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MLSS has been increased compared to 1 year ago.
Compared to 5 years ago, MLSS has more shares outstanding
MLSS has a worse debt/assets ratio than last year.
MLSS Yearly Shares OutstandingMLSS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MLSS Yearly Total Debt VS Total AssetsMLSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.40, we must say that MLSS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -8.40, MLSS is not doing good in the industry: 76.72% of the companies in the same industry are doing better.
MLSS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
MLSS has a better Debt to Equity ratio (0.01) than 68.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -8.4
ROIC/WACCN/A
WACC9.07%
MLSS Yearly LT Debt VS Equity VS FCFMLSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 2.48 indicates that MLSS has no problem at all paying its short term obligations.
MLSS's Current ratio of 2.48 is in line compared to the rest of the industry. MLSS outperforms 46.56% of its industry peers.
MLSS has a Quick Ratio of 1.15. This is a normal value and indicates that MLSS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MLSS (1.15) is worse than 71.96% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.15
MLSS Yearly Current Assets VS Current LiabilitesMLSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

MLSS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.15%, which is quite impressive.
The Revenue for MLSS has decreased by -12.21% in the past year. This is quite bad
Measured over the past years, MLSS shows a small growth in Revenue. The Revenue has been growing by 0.61% on average per year.
EPS 1Y (TTM)38.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.15%
Revenue 1Y (TTM)-12.21%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-10.95%

3.2 Future

Based on estimates for the next years, MLSS will show a very strong growth in Earnings Per Share. The EPS will grow by 24.37% on average per year.
The Revenue is expected to grow by 19.08% on average over the next years. This is quite good.
EPS Next Y49%
EPS Next 2Y24.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year17.97%
Revenue Next 2Y19.08%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MLSS Yearly Revenue VS EstimatesMLSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M 8M 10M
MLSS Yearly EPS VS EstimatesMLSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.05 -0.1 -0.15 -0.2 -0.25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MLSS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLSS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLSS Price Earnings VS Forward Price EarningsMLSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLSS Per share dataMLSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1

4.3 Compensation for Growth

MLSS's earnings are expected to grow with 24.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MLSS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MILESTONE SCIENTIFIC INC

NYSEARCA:MLSS (5/19/2025, 8:04:00 PM)

After market: 1.02 0 (0%)

1.02

+0.13 (+13.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-14 2025-05-14
Earnings (Next)08-13 2025-08-13
Inst Owners5.7%
Inst Owner Change-5.75%
Ins Owners6.89%
Ins Owner Change-0.09%
Market Cap79.95M
Analysts82.5
Price Target2.17 (112.75%)
Short Float %0.16%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-145.1%
Min EPS beat(2)-194.12%
Max EPS beat(2)-96.08%
EPS beat(4)1
Avg EPS beat(4)-96.08%
Min EPS beat(4)-194.12%
Max EPS beat(4)1.96%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.64%
Min Revenue beat(2)-25.64%
Max Revenue beat(2)-5.64%
Revenue beat(4)0
Avg Revenue beat(4)-17%
Min Revenue beat(4)-27.95%
Max Revenue beat(4)-5.64%
Revenue beat(8)2
Avg Revenue beat(8)-11.39%
Revenue beat(12)4
Avg Revenue beat(12)-11.49%
Revenue beat(16)6
Avg Revenue beat(16)-8.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.26
P/FCF N/A
P/OCF N/A
P/B 13.71
P/tB 14.06
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.11
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.11%
ROE -80.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.56%
FCFM N/A
ROA(3y)-57.54%
ROA(5y)-48.91%
ROE(3y)-84.14%
ROE(5y)-67.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.77%
GM growth 5Y1.76%
F-Score4
Asset Turnover0.88
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.93%
Cap/Sales 0.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 1.15
Altman-Z -8.4
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)17.16%
Cap/Depr(5y)20.45%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.15%
EPS Next Y49%
EPS Next 2Y24.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.21%
Revenue growth 3Y-5.73%
Revenue growth 5Y0.61%
Sales Q2Q%-10.95%
Revenue Next Year17.97%
Revenue Next 2Y19.08%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.18%
OCF growth 3YN/A
OCF growth 5YN/A